New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2014
10:00 EDTBBBY, WSO, TAM, SJR, MHFI, CRUS, APO, RBA, UN, SPH, REGN, PETM, ARG, HTZ, TITN, TMK, STCK, PL, XONEOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Airgas (ARG) downgraded to Sell from Neutral at Goldman... Cirrus Logic (CRUS) downgraded to Underperform from Sector Perform at Pacific Crest... ExOne (XONE) downgraded to Hold from Buy at Canaccord... McGraw Hill Financial (MHFI) downgraded to Hold from Buy at Benchmark Co... PetSmart (PETM) downgraded to Neutral from Buy at UBS... Protective Life (PL) downgraded to Market Perform from Outperform at Raymond James... Regeneron (REGN) downgraded to Market Perform from Outperform at BMO Capital... Shaw Communications (SJR) downgraded to Neutral from Buy at BofA/Merrill... Stock Building Supply (STCK) downgraded to Neutral from Buy at Goldman... Suburban Propane (SPH) downgraded to Sell from Neutral at Goldman... Taminco (TAM) downgraded to Neutral from Buy at Goldman... Torchmark (TMK) downgraded to Underperform from Market Perform at Raymond James... Unilever (UN) downgraded to Underweight from Neutral at JPMorgan... Watsco (WSO) downgraded to Sell from Neutral at Goldman... Titan Machinery (TITN) downgraded to Sell from Hold at Cantor... Ritchie Bros. (RBA) downgraded to Sell from Hold at Cantor... Bed Bath & Beyond (BBBY) downgraded to Neutral from Buy at Gilford Securities... Hertz (HTZ) downgraded to Neutral from Buy at Goldman... Apollo Global (APO) downgraded to Perform from Outperform at Oppenheimer.
News For ARG;CRUS;XONE;PETM;MHFI;PL;REGN;SJR;STCK;SPH;TAM;TMK;UN;WSO;TITN;RBA;BBBY;HTZ;APO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2015
13:56 EDTTMKTorchmark, Primerica could be targets for Japanese buyers, dealReporter says
Subscribe for More Information
08:01 EDTREGNAmgen pricing for Repatha competitive with Praluent, says Piper Jaffray
After the FDA announced last night that it has approved Amgen's (AMGN) Repatha injection, Piper Jaffray analyst Joshua Schimmer said that the drug's indications seem "generally in line" with those for Praluent from Regeneron (REGN) and Sanofi (SNY). Amgen disclosed an annual WAC of $14,100 for Repatha, which the analyst notes is about $500 per year below Praluent, but Schimmer said that the actual recognized price for each will ultimately be determined by discounting. Schimmer also noted that Amgen said it is working with payers and other purchasers on "innovative pricing programs," though he is uncertain if that means the company is working on a kind of "pay per performance" scheme. The analyst, who believes the market will prove large enough for both treatments, keeps a $200 price target and Overweight rating on Amgen shares.
August 27, 2015
19:14 EDTREGNExpress Scripts to cover both Repatha, Praluent for now, Bloomberg says
Subscribe for More Information
August 26, 2015
07:39 EDTAPOPiper Jaffray lowers estimates for asset managers below consensus
Subscribe for More Information
August 25, 2015
08:21 EDTREGNRegeneron has multiple catalysts, says Leerink
Subscribe for More Information
August 24, 2015
09:45 EDTARGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:23 EDTREGNRegeneron should be bought on pullbacks, says RBC Capital
Subscribe for More Information
06:59 EDTARGAirgas downgraded to Neutral from Outperform at Baird
Subscribe for More Information
August 23, 2015
12:35 EDTREGNBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 20, 2015
05:55 EDTCRUSCirrus Logic pullback a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Ruben Roy recommends using the recent pullback in shares of Cirrus Logic as a buying opportunity. The stock is down 23% from the post earnings highs in late July, Roy tells investors in a research note. After hosting investor meetings with Cirrus Logic CEO Jason Rhode, Roy believes increasing dollar content in upcoming handsets and revenue diversification will remain key themes for the company over the next 18 months. He views Cirrus as the "strongest beneficiary" from expanding voice activation applications in portable and mobile devices. Roy reiterates an Overweight rating on the stock with a $44 price target.
August 18, 2015
19:47 EDTAPOCaesars creditors give ultimatum to Apollo Global, Bloomberg says
Earlier this month, creditors opposed to Caesars Entertainment's (CZR) bankruptcy plan demanded that Apollo Global (APO) -- one of the company's owners -- relinquish control of the bankrupt unit's parent company, reports Bloomberg, citing two people with knowledge of the matter. In exchange, the creditors offered to withdraw several lawsuits related to the bankruptcy, said the sources. Apollo rejected the ultimatum, though sources noted that talks are continuing. Reference Link
16:07 EDTXONEExOne to open new Production Service Center in Sweden
Subscribe for More Information
10:07 EDTXONEHigh option volume stocks
High option volume stocks: CCOI XONE XDE OMER JMBA URBN W SCCO DKS ESPR FEYE W
August 17, 2015
08:02 EDTRBAGordon Brothers to sell assets of Hodges Trucking in conjunction w/ Ritchie Bros
Subscribe for More Information
06:22 EDTREGNPiper's Tenthoff sees select biotech names outperforming in second half
Piper Jaffray analyst Edward Tenthoff expects drug launches, clinical data read-outs and potential partnerships to drive outperformance for select biotech names in the second half of 2015. Despite some recent profit-taking, 2015 has been another strong year for biotech stocks, Tenthoff tells investors in a research note. Names with important second half of the year catalysts include Vertex (VRTX), Regeneron (REGN), Seattle Genetics (SGEN), Exelixis (EXEL), Sarepta (SRPT), Novavax (NVAX), Arrowhead (ARWR), Array BioPharma (ARRY), Alnylam (ALNY), Genocea (GNCA), CymaBay (CBAY), Idera Pharmaceuticals (IDRA), Vitae Pharmaceuticals (VTAE).

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use